CTLA4 and hepatocellular carcinoma: Later, combination therapies such as atezolizumab (anti-PD-L1) with bevacizumab [9] and dual immunotherapy with durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) [10] were also validated for first-line treatment in HCC.